BioCryst Pharmaceuticals, Inc. (BCRX): one to watch?

Wait — recent drop is from a single analyst downgrade over rising HAE-drug competition, not a company blow-up, but that risk is real and unresolved.

👀 WATCH Fundamentals70/100

Fell 20% in 7 trading day(s) — now $8.12

Why BCRX dropped

The immediate 7% single-day slide came after RBC Capital cut its rating from "outperform" to "sector perform" (target cut to $11 from $13), and this followed a similar move by Evercore ISI months earlier — both citing growing competition in the hereditary angioedema (HAE) market where BioCryst's main drug Orladeyo competes.

Fwd P/E 8.6Op margin 45.1%Rev growth 33.6%Debt/equity —Analyst upside 156.4%

How this scored 70/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Loss-making today, but operations are profitable (45.1%) and analysts expect positive earnings next year

✅ Generates cash Free cash flow $324M

✅ Not drowning in debt Debt/equity unknown (limit 200%)

✅ Can pay its bills Current ratio 2.3 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 11/25

Operating margin 45.1% 9/9

Net profit margin -40.9% 0/8

Return on equity unknown 2/8

Growth Is it getting bigger, or dying? 25/25

Revenue growth 33.6% 9/9

Earnings growth 1400.0% 8/8

Expected profit change 167.1% 8/8

Value Is it cheap right now? 17/25

Forward P/E 8.6 10/10

PEG ratio 9.4 0/8

Analyst target upside 156.4% 7/7

Balance sheet Will it survive? 17/25

Debt / equity unknown 3/10

Current ratio 2.3 7/8

Free cash flow $324M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for BCRX — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-09-14. Research only — not financial advice.